CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 377 enrolled
Drug / intervention
Dispersion ablation + PVI +2 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04702451
NCT04702451N/ACompleted
CompareCT.gov

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

Volta Medical·interventional·Posted Jan 8, 2021·Updated Sep 12, 2025

In Brief

A clinical study evaluating Dispersion ablation + PVI, VX1, and 1 other intervention for Atrial Fibrillation. Completed, enrolled 377 participants across 26 sites in 5 countries.

Detailed Summary

Atrial Fibrillation (AF) ablation is typically performed in predefined anatomic regions of the left atrium without attempting to identify patient-specific areas of interest. This procedure is referred to as Pulmonary Vein Isolation (PVI). The hypothesis in this Study is that a tailored ablation strategy targeting areas of spatio-temporal dispersion in combination with PVI is superior to an anatomical ablation strategy targeting PVI alone for the treatment of persistent AF.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesBelgium, France, Germany, Netherlands, United States
CollaboratorsFortrea, CardiaBase

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJan 8, 2021
Enrollment StartFeb 12, 2021
Primary CompletionDec 27, 2023
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.5 years ago

Interventions

Dispersion ablation + PVIprocedure

Ablation of spatio-temporal dispersion electrograms in combination with pulmonary vein antrum isolation

VX1device

VX1-based dispersion mapping

PVIprocedure

Pulmonary vein antrum isolation